Evidence map›Paper›PMID 29344362›Full record

ArticleBiomarker research2018

Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study.

Allison Meisner, Kathleen F Kerr, Heather Thiessen-Philbrook, Francis Perry Wilson, Amit X Garg, Michael G Shlipak, Peter Kavsak, Richard P Whitlock, Steven G Coca, Chirag R Parikh

Open access · goldAbstract read
In one paragraph

Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Allison Meisner1Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195 USA.
Kathleen F Kerr1Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195 USA.
Heather Thiessen-Philbrook2Program of Applied Translational Research, Yale University School of Medicine and VA Medical Center, 60 Temple Street, Suite 6C, New Haven, CT 06510 USA.
Francis Perry Wilson2Program of Applied Translational Research, Yale University School of Medicine and VA Medical Center, 60 Temple Street, Suite 6C, New Haven, CT 06510 USA.
Amit X Garg4Division of Nephrology, Department of Medicine and Department of Epidemiology and Biostatistics, Western University, London, Canada.
Michael G Shlipak6Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California at San Francisco School of Medicine, 4150 Clement Street, San Francisco, CA 94121 USA.
Peter Kavsak7Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1 Canada.
Richard P Whitlock8Department of Surgery, McMaster University, Hamilton, ON Canada.
Steven G Coca9Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1243, New York, NY 10029 USA.
Chirag R Parikh2Program of Applied Translational Research, Yale University School of Medicine and VA Medical Center, 60 Temple Street, Suite 6C, New Haven, CT 06510 USA.
McMaster University · CAUniversity of Washington · USYale University · USIcahn School of Medicine at Mount Sinai · USSan Francisco VA Medical Center · USVeterans Health Administration · USWestern University · CA

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Progression of Acute Kidney Injury to Chronic Kidney DiseaseU01DK082185 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2017
$5.1M
Optimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1M
Novel serum and urinary biomarkers of diabetic kidney diseaseR01DK096549 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2012 to 2016
$2.9M
Long-term Prognosis of Acute Kidney Injury in Cardiac SurgeryK23DK080132 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2008 to 2012
$957k
Mentoring Program for Translational and Patient Oriented Research in AKIK24DK090203 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2012 to 2016
$896k
Biomarkers of Kidney Injury: Statistical Methods for Risk Model Development and EvaluationF31DK108356 · NIDDK · UNIVERSITY OF WASHINGTON · PI MEISNER, ALLISON · 2015 to 2016
$78k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL085757NIDDK NIH HHS F31 DK108356NIDDK NIH HHS K23 DK080132NIDDK NIH HHS K24 DK090203NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK096549NIDDK NIH HHS R01 DK113191NIDDK NIH HHS U01 DK082185
6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is a frequent complication of cardiac surgery. We sought prognostic combinations of postoperative biomarkers measured within 6 h of surgery, potentially in combination with cardiopulmonary bypass time (to account for the degree of insult to the kidney). We used data from a large cohort of patients and adapted methods for developing biomarker combinations to account for the multicenter design of the study.

methodsThe primary endpoint was sustained mild AKI, defined as an increase of 50% or more in serum creatinine over preoperative levels lasting at least 2 days during the hospital stay. Severe AKI (secondary endpoint) was defined as a serum creatinine increase of 100% or more or dialysis during hospitalization. Data were from a cohort of 1219 adults undergoing cardiac surgery at 6 medical centers; among these, 117 developed sustained mild AKI and 60 developed severe AKI. We considered cardiopulmonary bypass time and 22 biomarkers as candidate predictors. We adapted Bayesian model averaging methods to develop center-adjusted combinations for sustained mild AKI by (1) maximizing the posterior model probability and (2) retaining predictors with posterior variable probabilities above 0.5. We used resampling-based methods to avoid optimistic bias in evaluating the biomarker combinations.

resultsThe maximum posterior model probability combination included plasma N-terminal-pro-B-type natriuretic peptide, plasma heart-type fatty acid binding protein, and change in serum creatinine from before to 0-6 h after surgery; the median probability combination additionally included plasma interleukin-6. The center-adjusted, optimism-corrected AUCs for these combinations were 0.80 (95% CI: 0.78, 0.87) and 0.81 (0.78, 0.87), respectively, for predicting sustained mild AKI, and 0.81 (0.76, 0.90) and 0.83 (0.76, 0.90), respectively, for predicting severe AKI. For these data, the Bayesian model averaging methods yielded combinations with prognostic capacity comparable to that achieved by standard frequentist methods but with more parsimonious models.

conclusionsPending external validation, the identified combinations could be used to identify individuals at high risk of AKI immediately after cardiac surgery and could facilitate clinical trials of renoprotective agents.

Indexed as

Acute kidney injuryBiomarkers combinationsCardiac surgeryPrognostic

Identifiers

PMID29344362
PMCPMC5767010
OpenAlexW2783774659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.